Results 211 to 220 of about 51,036 (300)

Australian consensus recommendations for the management of increased meningococcal infection risk in adults with neurological diseases treated with complement inhibitors

Internal Medicine Journal, EarlyView.
Abstract Complement inhibitor therapy carries a risk of serious infections, including meningococcal disease. Here we provide evidence‐based recommendations and expert consensus for immunisation and prophylactic treatment of patients receiving, or planning to receive, complement inhibitors for neurological conditions in the Australian setting.
Katherine A. Buzzard, Michael Barnett, Heidi Beadnall, Mirasol Forcadela, Lesley‐Ann Hall, Victoria G. Hall, Todd Hardy, Danny Hsu, Paul Kinsella, Mastura Monif, Sudarshini Ramanathan, Stephen W. Reddel, Sean Riminton, Douglas F. Johnson   +13 more
wiley   +1 more source

Cardiovascular Outcomes With Dupilumab Versus Omalizumab in Severe Asthma

Clinical &Experimental Allergy, EarlyView.
Po‐Cheng Shih, Chun‐Ting Lin, James Cheng Chung Wei   +2 more
wiley   +1 more source

Immune‐related adverse events with mogamulizumab in cutaneous T‐cell lymphoma: A multicentre study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In a nationwide multicentre study of 403 patients with cutaneous T‐cell lymphoma treated with mogamulizumab, non‐MAR immune‐related adverse events were reported in 8.4% of patients across responding centres. These events were diverse, sometimes severe or persistent, and could occur late during mogamulizumab treatment.
David Neubauer, Pascale Palassin, Caroline Ram‐Wolff, Adèle De Masson, Jeremie Delaleu, Diane Kottler, Florent Amatore, Henri Adamski, Claudia Bejar, Raphaël Janela‐Lapert, Emmanuella Guenova, Pauline Bernard, Coralie Lheure, Laurent Machet, Laura Troin, Gaëlle Quereux, Anne Pham‐Ledard, Sarah Faiz, Florent Grange, Yannick Le Corre, Arjen Nikkels, Stéphane Barete, Lorena Manea, Emmanuelle Amazan, Alexandre Tj Maria, Lionel Moulis, Olivier Dereure, Quentin Samaran, For the Groupe Français d'Étude des Lymphomes Cutanés (GFELC)   +28 more
wiley   +1 more source

Hair loss in the era of CGRP inhibition: emerging evidence, mechanisms, and clinical implications. [PDF]

Front Neurol
Antanaitytė A, Jokubaitis M, Jokubaitė J, Ryliškienė K.   +3 more
europepmc   +1 more source

Immune effector cell‐associated neurotoxicity syndrome (ICANS) during tebentafusp in metastatic uveal melanoma

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Laura Schreieder, Laura Jockel, Veronika Zenderowski, Ralf A. Linker, Sebastian Haferkamp, Elisabeth Bumes, Peter Hau, Konstantin Drexler   +7 more
wiley   +1 more source

GLP‐1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications

Journal of Internal Medicine, EarlyView.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists provide benefits in weight reduction, glycaemic control in Type 2 diabetes, and cardiovascular and renal outcomes. Their widespread use has given rise to concerns regarding rare but potentially serious adverse events.
Peter Ueda
wiley   +1 more source

Regional research priorities for medication safety and pharmacovigilance in gulf cooperation council countries: a modified Delphi consensus study. [PDF]

Saudi Pharm J
Assiri GA, Khawagi WY, Alewairdhi H, Alqenae FA, Bannan DF, Alshehri AA, Hamad A, Alraisi F, Alshehri GH.   +8 more
europepmc   +1 more source

Severe Thrombocytopenia Associated With Glucagon‐Like‐1 Receptor Agonists (GPL‐1RA): A SONAR Report

Diabetes, Obesity and Metabolism, EarlyView.
Charles L. Bennett, Chadi Nabhan, Demir Uslu, Yogitha Dadi, David Aboulafia, Barbara Senger, Joseph Magagnoli, Kelvin Rojas, Gurdeep Singh, Linda Martin, Edward Smith, Samuel Ruder, Chien‐Hsiang Weng, Nikhil Uppal, Mia Lynch, James B. Bussel   +15 more
wiley   +1 more source

Parasomnias and sleep‐related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont, Vanessa Bloch, Agnès Lillo‐Lelouet, Christine Le Beller, Pierre A. Geoffroy, Marc Veyrier   +5 more
wiley   +1 more source

Teaching Student Veterinary Professionals About Pharmacovigilance: A Survey of UK Veterinary Educators

Journal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT Adverse drug event (ADE) reports submitted by veterinary professionals are essential for monitoring the safety and efficacy of marketed veterinary products. Despite this, the majority of veterinary ADEs are not reported. Further education on the topic of pharmacovigilance has been widely explored in human healthcare as a potential facilitator ...
Heather Grieve, Martin Hawes, Catherine Hemingway, Elizabeth Wright, David Killick   +4 more
wiley   +1 more source